JP2015517556A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517556A5 JP2015517556A5 JP2015513185A JP2015513185A JP2015517556A5 JP 2015517556 A5 JP2015517556 A5 JP 2015517556A5 JP 2015513185 A JP2015513185 A JP 2015513185A JP 2015513185 A JP2015513185 A JP 2015513185A JP 2015517556 A5 JP2015517556 A5 JP 2015517556A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- guanidine
- viscosity
- therapeutic agent
- biological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 87
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 56
- 150000002357 guanidines Chemical class 0.000 claims description 36
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 26
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 25
- 229940124597 therapeutic agent Drugs 0.000 claims description 23
- 238000002347 injection Methods 0.000 claims description 19
- 239000007924 injection Substances 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 229930064664 L-arginine Natural products 0.000 claims description 4
- 235000014852 L-arginine Nutrition 0.000 claims description 4
- 125000003636 chemical group Chemical group 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 210000004087 cornea Anatomy 0.000 claims description 3
- 210000003786 sclera Anatomy 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000009697 arginine Nutrition 0.000 claims description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- 125000000647 trehalose group Chemical group 0.000 claims description 2
- 239000011149 active material Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651588P | 2012-05-25 | 2012-05-25 | |
| US61/651,588 | 2012-05-25 | ||
| PCT/EP2013/060649 WO2013174936A1 (en) | 2012-05-25 | 2013-05-23 | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017071601A Division JP6405406B2 (ja) | 2012-05-25 | 2017-03-31 | 生物学的治療薬およびグアニジンまたはグアニジン誘導体を含む水性医薬組成物、並びに該組成物を含む注射剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015517556A JP2015517556A (ja) | 2015-06-22 |
| JP2015517556A5 true JP2015517556A5 (enExample) | 2016-05-12 |
| JP6250646B2 JP6250646B2 (ja) | 2017-12-20 |
Family
ID=48534372
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015513185A Active JP6250646B2 (ja) | 2012-05-25 | 2013-05-23 | 生物学的治療薬およびグアニジンまたはグアニジン誘導体を含む水性医薬組成物、並びに該組成物を含む注射剤 |
| JP2017071601A Expired - Fee Related JP6405406B2 (ja) | 2012-05-25 | 2017-03-31 | 生物学的治療薬およびグアニジンまたはグアニジン誘導体を含む水性医薬組成物、並びに該組成物を含む注射剤 |
| JP2018172328A Pending JP2018193406A (ja) | 2012-05-25 | 2018-09-14 | 生物学的治療薬およびグアニジンまたはグアニジン誘導体を含む水性医薬組成物、並びに該組成物を含む注射剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017071601A Expired - Fee Related JP6405406B2 (ja) | 2012-05-25 | 2017-03-31 | 生物学的治療薬およびグアニジンまたはグアニジン誘導体を含む水性医薬組成物、並びに該組成物を含む注射剤 |
| JP2018172328A Pending JP2018193406A (ja) | 2012-05-25 | 2018-09-14 | 生物学的治療薬およびグアニジンまたはグアニジン誘導体を含む水性医薬組成物、並びに該組成物を含む注射剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10010513B2 (enExample) |
| EP (1) | EP2854760B1 (enExample) |
| JP (3) | JP6250646B2 (enExample) |
| KR (1) | KR20150024301A (enExample) |
| CN (1) | CN104220047B (enExample) |
| AR (1) | AR091155A1 (enExample) |
| AU (2) | AU2013265255B2 (enExample) |
| CA (1) | CA2866232A1 (enExample) |
| CL (1) | CL2014003148A1 (enExample) |
| CO (1) | CO7270463A2 (enExample) |
| ES (1) | ES2706059T3 (enExample) |
| MX (1) | MX2014014318A (enExample) |
| PH (1) | PH12014502352A1 (enExample) |
| RU (1) | RU2014152803A (enExample) |
| WO (1) | WO2013174936A1 (enExample) |
| ZA (1) | ZA201406403B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105164204A (zh) | 2012-11-21 | 2015-12-16 | 路易斯维尔大学研究基金会 | 用于降低氧化损伤的组合物和方法 |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| ES2769783T3 (es) * | 2014-03-11 | 2020-06-29 | Green Cross Holdings Corp | Procedimiento de purificación de inmunoglobulina |
| AU2015325055B2 (en) * | 2014-10-01 | 2021-02-25 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| EP3256136A4 (en) | 2015-02-09 | 2018-11-21 | University Of Louisville Research Foundation, Inc. | Ophthalmic compositions and methods for reducing oxidative damage to an eye lens |
| TW201722437A (zh) * | 2015-11-30 | 2017-07-01 | Rohto Pharma | 眼科組成物 |
| MY191668A (en) | 2016-06-14 | 2022-07-06 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| ES2968923T3 (es) | 2016-08-10 | 2024-05-14 | Celltrion Inc | Preparación farmacéutica líquida estable de anticuerpo contra el virus de la gripe |
| KR102262743B1 (ko) | 2017-07-07 | 2021-06-09 | 에이치케이이노엔 주식회사 | 주사용 조성물 |
| GB201713660D0 (en) * | 2017-08-25 | 2017-10-11 | Kalvista Pharmaceuticals Ltd | Pharmaceutical compositions |
| JP2021506241A (ja) | 2017-12-13 | 2021-02-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗ｃ５抗体組み合わせ物およびその使用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364884A (en) * | 1993-01-21 | 1994-11-15 | Baylor College Of Medicine | Arginine compounds as ocular hypotensive agents |
| US5658948A (en) * | 1994-03-02 | 1997-08-19 | Allergan | Enhancement of benzalkonium chloride preservative activity in formulations containing an incompatible drug using amino acids having net positive charge |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6462071B1 (en) * | 2000-03-02 | 2002-10-08 | Vitreo-Retinal Technologies, Inc. | Agents for intravitreal administration to treat or prevent disorders of the eye |
| AU2001271417B2 (en) | 2000-08-30 | 2006-10-05 | Johns Hopkins University | Devices for intraocular drug delivery |
| AU2003293543A1 (en) * | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| EP2129681A2 (en) * | 2007-03-22 | 2009-12-09 | Novartis Ag | C5 antigens and uses thereof |
| WO2010015608A1 (en) | 2008-08-05 | 2010-02-11 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c5 |
| ES2765657T3 (es) * | 2009-12-21 | 2020-06-10 | Hoffmann La Roche | Formulación farmacéutica de bevacizumab |
| WO2011104381A2 (en) * | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Stable antibody containing compositions |
-
2013
- 2013-05-23 AU AU2013265255A patent/AU2013265255B2/en active Active
- 2013-05-23 EP EP13725348.0A patent/EP2854760B1/en active Active
- 2013-05-23 MX MX2014014318A patent/MX2014014318A/es unknown
- 2013-05-23 US US13/900,724 patent/US10010513B2/en active Active
- 2013-05-23 RU RU2014152803A patent/RU2014152803A/ru not_active Application Discontinuation
- 2013-05-23 CA CA2866232A patent/CA2866232A1/en not_active Abandoned
- 2013-05-23 JP JP2015513185A patent/JP6250646B2/ja active Active
- 2013-05-23 KR KR20147026263A patent/KR20150024301A/ko not_active Ceased
- 2013-05-23 WO PCT/EP2013/060649 patent/WO2013174936A1/en not_active Ceased
- 2013-05-23 CN CN201380020203.0A patent/CN104220047B/zh active Active
- 2013-05-23 ES ES13725348T patent/ES2706059T3/es active Active
- 2013-05-24 AR ARP130101819 patent/AR091155A1/es unknown
-
2014
- 2014-09-01 ZA ZA2014/06403A patent/ZA201406403B/en unknown
- 2014-10-21 PH PH12014502352A patent/PH12014502352A1/en unknown
- 2014-11-20 CL CL2014003148A patent/CL2014003148A1/es unknown
- 2014-11-27 CO CO14261585A patent/CO7270463A2/es unknown
-
2017
- 2017-03-31 JP JP2017071601A patent/JP6405406B2/ja not_active Expired - Fee Related
-
2018
- 2018-06-04 AU AU2018203929A patent/AU2018203929A1/en not_active Abandoned
- 2018-09-14 JP JP2018172328A patent/JP2018193406A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517556A5 (enExample) | ||
| JP6405406B2 (ja) | 生物学的治療薬およびグアニジンまたはグアニジン誘導体を含む水性医薬組成物、並びに該組成物を含む注射剤 | |
| JP6229007B2 (ja) | 濃縮されたタンパク質製剤およびその使用 | |
| TWI533884B (zh) | 含抗－介白素－６受體（ｉｌ－６ｒ）抗體之安定調配物 | |
| FI3209681T3 (fi) | Peptidivariantteja käsittäviä farmaseuttisia koostumuksia ja niiden käyttömenetelmiä | |
| CA2672902A1 (en) | Formulations | |
| HRP20241131T1 (hr) | Visokokoncentrirane formulacije inhibitornih antitijela masp-2 niske viskoznosti, pribori i metode | |
| JP2010513522A5 (enExample) | ||
| RU2015132431A (ru) | Составы, содержащие антитела | |
| KR20130079486A (ko) | 항―ｎｇｆ 항체를 함유하는 안정화된 제형 | |
| RU2020112952A (ru) | Жидкая фармацевтическая композиция | |
| JP2013521296A5 (enExample) | ||
| JP6026002B2 (ja) | タンパク質とＦｃドメインを融合した融合タンパク質の安定化用組成物 | |
| RU2010141542A (ru) | Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций | |
| ES2806946T3 (es) | Composición farmacéutica estable de la proteína de fusión TNFR:Fc etanercept | |
| BR112016025126B1 (pt) | Composição aquosa compreendendo anticorpo neutralizante de gmcsf, e uso da mesma | |
| HRP20191044T1 (hr) | Oftalmološki pripravci i njihova uporaba | |
| TW201716086A (zh) | 含有液態醫藥配製物之預填充針筒 | |
| RU2008129635A (ru) | Ингибиторы ссr9 активности | |
| JP5922609B2 (ja) | ２−アミノ−３−（４−ブロモベンゾイル）フェニル酢酸含有水性組成物 | |
| CA2975633A1 (en) | Stable pharmaceutical solution formulation of glp-1r antibody fusion protein | |
| RU2016144342A (ru) | Стабильные композиции нейроактивных пептидов | |
| AR078928A1 (es) | Formulacion oftalmica liquida que comprende lactamas gamma sustituidas, articulo de fabricacion que la comprende y su uso para la preparacion de un medicamento util para tratar la hipertension ocular | |
| JP2022544216A (ja) | 抗体を含む新規組成物 | |
| RU2017134594A (ru) | Фармацевтическая композиция, включающая полипептид |